CytomX Therapeutics (CTMX) Treasury Shares (2014 - 2026)

CytomX Therapeutics' Treasury Shares history runs 8 years deep, the most recent figure standing at $2.7 million for Q1 2026.

• Quarterly Treasury Shares fell 4.78% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (down 4.78% YoY) and the FY2025 annual result came in at $2.9 million, up 57.09% from the prior year.
• Treasury Shares was $2.7 million for Q1 2026 at CytomX Therapeutics, down from $2.9 million in the prior quarter.
• Across five years, Treasury Shares topped out at $2.9 million in Q4 2025 and bottomed at $397500.0 in Q3 2022.
• A 5-year average of $1.8 million and a median of $1.7 million in 2023 frame the typical range for Treasury Shares.
• Annual changes were most pronounced in 2023 — Treasury Shares soared 303.05% — and 2024, when it dropped 15.03%.
• CytomX Therapeutics' Treasury Shares stood at $1.2 million in 2022, then increased by 15.47% to $1.4 million in 2023, then decreased by 15.03% to $1.2 million in 2024, then surged by 144.64% to $2.9 million in 2025, then fell by 8.72% to $2.7 million in 2026.
• Business Quant data shows CTMX's Treasury Shares at $2.7 million in Q1 2026, $2.9 million in Q4 2025, and $2.9 million in Q3 2025.